<DOC>
	<DOC>NCT00664742</DOC>
	<brief_summary>This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome</brief_summary>
	<brief_title>The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>≥ 3 criteria for metabolic syndrome National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III criteria) Triglyceride (TG) &lt; 400 mg/dl and Low Density LipoproteinCholesterol (LDLC) 100 mg/dl to 190 mg/dl Written informed consent for participating in the study Severe renal disease or renal dysfunction Chronic liver disease or liver function impairment Inflammatory muscle dysfunction or findings of muscle problems Severe cardiac failure Other protocol defined inclusion exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Metabolic syndrome,dyslipidemia,fluvastatin extended release</keyword>
</DOC>